AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10714142 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive tasks (ease of learning judgments, feeling of knowing judgments, judgments of learning, text comprehension monitoring)
Number of subjects: 0
Study 9178732 — intervention group
Group type: COMPARATOR
Intervention: Zinc therapy for Wilson's disease (5 years or longer)
Number of subjects: 0
Study 9178732 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy for Wilson's disease (1 year)
Number of subjects: 0
Study 9178732 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy for Wilson's disease (up to 15 years)
Number of subjects: 0
Study 1545850 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 432
Study 1545850 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin
Number of subjects: 432
Study 3929328 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) insufflation
Number of subjects: 151
Study 3929328 — intervention group
Group type: COMPARATOR
Intervention: Room air insufflation
Number of subjects: 151
Study 29232980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physiotherapy
Number of subjects: 40
Study 29232980 — intervention group
Group type: COMPARATOR
Intervention: Land physiotherapy
Number of subjects: 40
Study 28444995 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD)
Number of subjects: 3385
Study 25583364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (12-20 mg)
Number of subjects: 108
Study 25583364 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine (400-600 mg)
Number of subjects: 108
Study 25583364 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 108
Study 23474283 — intervention group
Group type: EXPERIMENTAL
Intervention: FMPP (fermented milk product with probiotic)
Number of subjects: 36
Study 23474283 — intervention group
Group type: COMPARATOR
Intervention: Nonfermented milk product (control)
Number of subjects: 36
Study 23474283 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 36
Study 21879467 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX® BMI
Number of subjects: 1608
Study 21879467 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX® BMD
Number of subjects: 1608
Study 21879467 — intervention group
Group type: COMPARATOR
Intervention: Previous fractures
Number of subjects: 1608
Study 18253752 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite markers (specifically 1805A09 (D18S0325i) and 1806D05 (D18S0181i))
Number of subjects: 720
Study 18253752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density association mapping with 14 additional microsatellite markers
Number of subjects: 720
Study 16646293 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with POF
Number of subjects: 30
Study 16646293 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women (35 subjects)
Number of subjects: 30
Study 16646293 — intervention group
Group type: COMPARATOR
Intervention: Healthy fertile women (27 subjects)
Number of subjects: 30
Study 14503664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal doses of IS-159 (1, 2, 4, and 6 mg) administered twice at an interval of 4 hours
Number of subjects: 17
Study 10818174 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution computed tomography (HRCT)
Number of subjects: 36
Study 8992089 — intervention group
Group type: EXPERIMENTAL
Intervention: dexpanthenol-containing artificial tears (Siccaprotect)
Number of subjects: 50
Study 8992089 — intervention group
Group type: COMPARATOR
Intervention: dexpanthenol-free eye drops
Number of subjects: 50
Study 1510394 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime alone
Number of subjects: 127
Study 1510394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus vancomycin
Number of subjects: 127
Study 6418181 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release capsule of ketoprofen lysine (160 mg)
Number of subjects: 8
Study 6418181 — intervention group
Group type: COMPARATOR
Intervention: Conventional capsules of ketoprofen lysine (Artrosilene®) (160 mg)
Number of subjects: 8
Study 31081485 — intervention group
Group type: EXPERIMENTAL
Intervention: ParkinSong intervention (weekly dosage)
Number of subjects: 75
Study 31081485 — intervention group
Group type: EXPERIMENTAL
Intervention: ParkinSong intervention (monthly dosage)
Number of subjects: 75
Study 31081485 — intervention group
Group type: EXPERIMENTAL
Intervention: ParkinSong intervention
Number of subjects: 75
Study 31081485 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment control groups
Number of subjects: 75
Study 30139035 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone group (H group)
Number of subjects: 180
Study 30139035 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone supplement with dexmedetomidine 1 μg/kg group (D1 group)
Number of subjects: 180
Study 30139035 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone supplement with dexmedetomidine 2 μg/kg group (D2 group)
Number of subjects: 180
Study 25954844 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral A. montana (Alpine Pharmaceuticals)
Number of subjects: 22
Study 25954844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24375070 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg loxapine
Number of subjects: 48
Study 24375070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24375070 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (positive control)
Number of subjects: 48
Study 21808284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray nicotine replacement therapy
Number of subjects: 0
Study 21808284 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study 21808284 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nicotine replacement therapy
Number of subjects: 0
Study 21808284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21808284 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (including all interventions)
Number of subjects: 0
Study 20949341 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules taken intact with water under fed conditions
Number of subjects: 36
Study 20949341 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules taken intact with water under fasting conditions
Number of subjects: 36
Study 20949341 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules sprinkled on apple sauce
Number of subjects: 36
Study 20949341 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules under all treatment conditions
Number of subjects: 36
Study 17619791 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS), beclomethasone dipropionate 250 microg/day
Number of subjects: 85
Study 17619791 — intervention group
Group type: COMPARATOR
Intervention: Short-acting beta2 agonists as needed
Number of subjects: 85
Study 15895834 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental injection of 0.5 mL of hypertonic (6%) saline
Number of subjects: 12
Study 15895834 — intervention group
Group type: COMPARATOR
Intervention: Control injection of 0.5 mL isotonic (0.9%) saline
Number of subjects: 12
Study 11953554 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair climbing
Number of subjects: 46
Study 11300578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bad news with indefinite consequences
Number of subjects: 0
Study 11300578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bad news with definite consequences
Number of subjects: 0
Study 11300578 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient as a friend
Number of subjects: 0
Study 11300578 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient as a stranger
Number of subjects: 0
Study 11300578 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral responsibility to transmit the news
Number of subjects: 0
Study 11300578 — intervention group
Group type: EXPERIMENTAL
Intervention: Good news transmission
Number of subjects: 0
Study 9202087 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral zinc as zinc sulfate, given daily for up to 7 months
Number of subjects: 85
Study 9202087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 8434669 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 mg intravenous cocaine
Number of subjects: 8
Study 8434669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3323274 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbent gelling material disposable diapers
Number of subjects: 1614
Study 3323274 — intervention group
Group type: COMPARATOR
Intervention: Conventional disposable diapers
Number of subjects: 1614
Study 3323274 — intervention group
Group type: COMPARATOR
Intervention: Home-laundered cloth diapers
Number of subjects: 1614
Study 27927036 — intervention group
Group type: EXPERIMENTAL
Intervention: REHACOP cognitive rehabilitation programme
Number of subjects: 42
Study 27927036 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 42
Study 26844988 — intervention group
Group type: EXPERIMENTAL
Intervention: Big Data research applications
Number of subjects: 0
Study 26844988 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of large, multicenter, and high-quality databases
Number of subjects: 0
Study 26844988 — intervention group
Group type: EXPERIMENTAL
Intervention: Big Data research
Number of subjects: 0
Study 23621170 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of two applications per week (group A)
Number of subjects: 885
Study 23621170 — intervention group
Group type: COMPARATOR
Intervention: On-demand therapy (group B)
Number of subjects: 885
Study 23878826 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based (EndoRez)
Number of subjects: 45
Study 23878826 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer-based (Activ GP)
Number of subjects: 45
Study 23878826 — intervention group
Group type: COMPARATOR
Intervention: Conventional gutta-percha plus pulp sealer (GP/EWT)
Number of subjects: 45
Study 20080875 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month weight loss intervention (n = 159, mean weight loss = -4.8 kg)
Number of subjects: 318
Study 20080875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not randomized to weight loss intervention, n = 159, mean weight loss = -1.4 kg)
Number of subjects: 318
Study 17678570 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-based capsules (35 mg isoflavones equivalent aglycone)
Number of subjects: 12
Study 17678570 — intervention group
Group type: COMPARATOR
Intervention: Soya-based cheese (35 mg isoflavones equivalent aglycone)
Number of subjects: 12
Study 15808260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Beriplast P)
Number of subjects: 22
Study 15808260 — intervention group
Group type: COMPARATOR
Intervention: Nylon 10-0 suture
Number of subjects: 22
Study 12959436 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 47
Study 10553821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 0.25 mg IV bolus
Number of subjects: 40
Study 10553821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 0.50 mg IV bolus
Number of subjects: 40
Study 10553821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 1.00 mg IV bolus
Number of subjects: 40
Study 10553821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 2.00 mg IV bolus
Number of subjects: 40
Study 10553821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (all doses)
Number of subjects: 40
Study 8549180 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 16
Study 8549180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2062546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 10
Study 2062546 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study 29855695 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (group A, immunotherapy arm)
Number of subjects: 0
Study 29855695 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (group B, control arm)
Number of subjects: 0
Study 26818932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (group meetings)
Number of subjects: 0
Study 24434948 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin A supplementation (5,000 IU vitamin A/kg/day)
Number of subjects: 0
Study 24434948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21365461 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 5454
Study 21365461 — intervention group
Group type: COMPARATOR
Intervention: PPI users
Number of subjects: 5454
Study 21365461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5454
Study 20860888 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (SSRIs prescribed by GP)
Number of subjects: 254
Study 20860888 — intervention group
Group type: COMPARATOR
Intervention: Listening visits (non-directive counselling)
Number of subjects: 254
Study 17473917 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (2.1, 70, 210 or 630 mg)
Number of subjects: 23
Study 17473917 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (70, 210, 630 mg)
Number of subjects: 23
Study 17473917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16358382 — intervention group
Group type: COMPARATOR
Intervention: EEG power in MCI patients at rest
Number of subjects: 35
Study 16358382 — intervention group
Group type: COMPARATOR
Intervention: EEG power in MCI patients during working memory tasks
Number of subjects: 35
Study 16358382 — intervention group
Group type: COMPARATOR
Intervention: EEG coherence in MCI patients during working memory tasks
Number of subjects: 35
Study 16358382 — intervention group
Group type: COMPARATOR
Intervention: EEG coherence in MCI patients at rest
Number of subjects: 35
Study 16358382 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of EEG powers and MMSE scores
Number of subjects: 35
Study 12213868 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 19
Study 12213868 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 9615244 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial pilot campaign exposure
Number of subjects: 0
Study 9615244 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive campaign exposure
Number of subjects: 0
Study 9615244 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' exposure to comprehensive campaign
Number of subjects: 0
Study 7647732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 8 mg/24 h
Number of subjects: 14
Study 7647732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2515594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine tablets 400 mg b.i.d.
Number of subjects: 17
Study 2515594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine suspension
Number of subjects: 17
Study 2515594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 350346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine 24 mg/day
Number of subjects: 29
Study 350346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine 48 mg/day
Number of subjects: 29
Study 350346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31791307 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstainers (self-reported 7-day point prevalence abstinence)
Number of subjects: 99
Study 31791307 — intervention group
Group type: COMPARATOR
Intervention: Non-abstainers (continued smoking)
Number of subjects: 99
Study 26911365 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-time stress scans
Number of subjects: 80
Study 26911365 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-time scans
Number of subjects: 80
Study 26911365 — intervention group
Group type: COMPARATOR
Intervention: Quarter-time scans
Number of subjects: 80
Study 26911365 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced radiopharmaceutical activity to 25% of reference
Number of subjects: 80
Study 26911365 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced radiopharmaceutical activity to 50%
Number of subjects: 80
Study 25854012 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to Sanyinjiao (SP 6), Zigong (EX CA 1), Zhongji (CV 3), and Guanyuan (CV 4), treatment given once every two days until egg collection, needles retained for 30 min each time
Number of subjects: 66
Study 25854012 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 66
Study 23980846 — intervention group
Group type: EXPERIMENTAL
Intervention: Black currant seed oil (BCSO) supplementation
Number of subjects: 61
Study 23980846 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 61
Study 23980846 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis status of mothers
Number of subjects: 61
Study 23980846 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis status of infants
Number of subjects: 61
Study 21720656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetaphil RestoradermTM Moisturizer (CRM)
Number of subjects: 0
Study 21720656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetaphil RestoradermTM Moisturizer (CRM) with topical steroid
Number of subjects: 0
Study 19246088 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty treatment
Number of subjects: 300
Study 19246088 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical care
Number of subjects: 300
Study 19246088 — intervention group
Group type: COMPARATOR
Intervention: Comparison between kyphoplasty and non-surgical care
Number of subjects: 300
Study 19246088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 300
Study 17467008 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized antipsychotic treatment
Number of subjects: 20
Study 17467008 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20
Study 15011764 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 74
Study 15011764 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 74
Study 11405347 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study 11405347 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study 11405347 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate end-points
Number of subjects: 0
Study 11405347 — intervention group
Group type: EXPERIMENTAL
Intervention: Central registry of observational trials
Number of subjects: 0
Study 8989024 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a rate of 1 mg.kg‐1.h‐1
Number of subjects: 10
Study 8989024 — intervention group
Group type: COMPARATOR
Intervention: Intralipid 0.1 ml.kg‐1.h‐1
Number of subjects: 10
Study 8480730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte plus sucralfate 1 g tds
Number of subjects: 259
Study 8480730 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte plus placebo
Number of subjects: 259
Study 8480730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 259
Study 3121354 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms buserelin
Number of subjects: 24
Study 3121354 — intervention group
Group type: COMPARATOR
Intervention: Saline spray (placebo control)
Number of subjects: 24
Study 31190493 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at 'reflection points' of the affected side and local acupoints in acute phase, with electroacupuncture in stationary phase and Zusanli (ST 36) in recovery phase.
Number of subjects: 90
Study 31190493 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture at Yifeng (TE 17) of the affected side and local acupoints, with electroacupuncture in stationary phase and Zusanli (ST 36) in recovery phase.
Number of subjects: 90
Study 31190493 — intervention group
Group type: COMPARATOR
Intervention: Ultrashort wave on Yifeng (TE 17) of the affected side, with same treatment as group B in stationary and recovery phases.
Number of subjects: 90
Study 28161352 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 0
Study 28161352 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg (escalated to 10 mg at week 6)
Number of subjects: 0
Study 28161352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25441247 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 271
Study 25441247 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 Propofol/Ketamine
Number of subjects: 271
Study 25441247 — intervention group
Group type: EXPERIMENTAL
Intervention: 4:1 Propofol/Ketamine
Number of subjects: 271
Study 23837269 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed standard written and verbal instructions
Number of subjects: 108
Study 23837269 — intervention group
Group type: COMPARATOR
Intervention: Detailed standard written instructions only
Number of subjects: 108
Study 23837269 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator experience (varied levels)
Number of subjects: 108
Study 23837269 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient sex (male/female)
Number of subjects: 108
Study 21967317 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I treatment (50 μg/kg twice daily)
Number of subjects: 16
Study 21967317 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 19833270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 73
Study 19833270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 73